摘要
目的:探讨多西他赛联合铂类药物治疗晚期卵巢癌的临床效果。方法:以60例晚期卵巢癌患者中作为研究对象,均实行化学治疗:将采取多西他赛联合顺铂方案者设为对照组(n=30),将采取多西他赛联合洛铂方案者设为研究组(n=30),比较疗效、安全性。结果:①研究组患者近期化疗有效率(93.33%)与对照组(90.00%)相比无统计学差异(P>0.05);②研究组Ⅲ~Ⅳ级不良反应发生率(25.00%)明显低于对照组(83.33%),P<0.05。结论:晚期卵巢癌患者在化疗中适宜选用多西他赛联合洛铂方案,其近期化疗效果肯定,不良反应相对轻微。
Objective:To investigate the clinical effect of docetaxel combined with platinum drugs in the treatment of advanced ovarian cancer.Methods:60 patients with advanced ovarian cancer were treated with chemotherapy:the patients who received docetaxel combined with cisplatin were set as the control group(n=30),and the patients who received docetaxel combined with lotplatin were set as the study group(n=30).The efficacy and safety were compared.Results:①there was no significant difference in the effective rate of recent chemotherapy between the study group(93.33%)and the control group(90.00%),P>0.05;②the incidence of grade Ⅲ-Ⅳ adverse reactions in the study group(25.00%)was significantly lower than that in the control group(83.33%),P<0.05.Conclusion:Docetaxel combined with loplatin is suitable for advanced ovarian cancer patients in chemotherapy.Its short-term chemotherapy effect is positive,and the adverse reactions are relatively slight.
作者
胡萍
HU Ping(Department of Gynecology,Pingxiang People’s Hospital,Pingxiang Jiangxi 337000,China)
出处
《药品评价》
CAS
2019年第16期4-5,共2页
Drug Evaluation
关键词
晚期
卵巢癌
多西他赛
洛铂
顺铂
不良反应
Late Period
Ovarian Cancer
Docetaxel
Lobaplatin
Cisplatin
Adverse Reaction
